Pharmacokinetics and Tolerability of a Single Dose of Apraglutide, a Novel, Long-Acting, Synthetic glucagon-like peptide-2 Analog With a Unique Pharmacologic Profile, in Individuals With Impaired Renal Function.

What Was Tested

This phase 1 clinical trial looks at Glucagon.

Renal impairment is a common complication in patients with short bowel syndrome with intestinal failure (SBS-IF).

Glucagon-like peptide-2 analogs, such as apraglutide, have been developed as a treatment option for SBS-IF.

Who Took Part

The study group was 8 individuals.

PubMed indexes the participants as adults, middle-aged adults and older adults, both men and women.

How the Study Was Run

The design is described as open-label, multicenter and parallel-group.

Being open-label, the Glucagon study did not mask who received what.

Running at several centres spread the Glucagon study over different clinics and patient groups.

Groups ran in parallel: each of the individuals stayed in one arm throughout.

What Was Measured

Renal impairment is a common complication in patients with short bowel syndrome with intestinal failure (SBS-IF).

This study assessed the potential for apraglutide overexposure in individuals with severely impaired renal function versus healthy volunteers with normal renal function.

The subject headings attached to it are Renal Insufficiency, Area Under Curve, Glucagon-Like Peptide 2 and Short Bowel Syndrome.

Author keywords: apraglutide, drug exposure and renal impairment.

What This Means in Plain Language

The paper is an open-label, multicenter and parallel-group study of Glucagon in 8 individuals.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The publication is from 2024 (Journal of clinical pharmacology), a journal based in England.

More context: the Glucagon compound page, all human trials.